Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of pridopidine in adults with early, rapidly progressive ALS
MOH_2026-01-14_015602Phase 3Recruiting
- Sponsor
- Prilenia Therapeutics
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Pridopidine with Placebo (2 arms). Started Dec 2025; status: recruiting.
02
Drugs
pridopidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2026-01-14_015602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-14_015602.